Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
Author: MACHADO, Melissa Pereira
TOMAZ, Juarez Pires
SOUZA, Cármino Antonio de
VIGORITO, Afonso Celso
DELAMAIN, Marcia Torresan
BENDIT, Israel
PEREIRA, Noemi Farah
PAGNANO, Katia Borgia Barbosa
Abstract: BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with imatinib in the chronic phase and correlate the response to therapy and event-free survival. METHODS: BCR-ABL levels were measured in peripheral blood cell samples using Real time PCR at diagnosis and then every 3 months after starting therapy with imatinib. Major molecular response was defined as a three-log reduction from the standardized baseline value. Major molecular response values were adjusted to international scale using a conversion factor of 1.19. The results are reported as a BCR-ABL/ABL ratio (%). RESULTS: Hematological, major cytogenetic and complete cytogenetic responses were achieved by 57 (95%), 45 (75%) and 38 (63%) patients, respectively. Twenty-four out of sixty patients achieved a major molecular response (40%) in a median time of 8.5 months. Overall survival and event free survival were higher for patients with (100%) versus patients without (77%) a complete cytogenetic response (p-value = 0.01) at 48 months. Patients with complete cytogenetic response and major molecular response had a higher event free survival compared to patients with complete cytogenetic response but without major molecular response (p-value = 0.007). CONCLUSION: In conclusion, the prognostic impact of achieving complete cytogenetic response and a major molecular response and also the importance of molecular monitoring in the follow-up of chronic myeloid leukemia patients were demonstrated.
Subject: Polymerase chain reaction
Leukemia, myelogenous, chronic, BCR-ABL positive
Country: Brasil
Editor: Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea
Citation: Revista Brasileira de Hematologia e Hemoterapia, v.33, n.3, p.211-215, 2011
Rights: aberto
Identifier DOI: 10.5581/1516-8484.20110056
Date Issue: 2011
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
art_BENDIT_Monitoring_of_BCR-ABL_levels_in_chronic_myeloid_2011.pdfpublished version343.96 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.